Attached please find the presentation for today’s webinar.  An FAQ document will be provided post webinar for any questions submitted to the ProviderOutreach@esrxcommunications.com.

Effective January 1, 2017, CVS Caremark will add Buprenorphine/Opioid to its DUR edits. Buprenorphine sublingual (SL) tablets and buprenorphine/naloxone SL film/tablets are indicated for the treatment of opioid dependency. Use of these products should be part of a complete treatment plan, which includes counseling and psychosocial support.

*Please see attached PDF for more information.

Effective January 1, 2017, CVS Caremark® will begin to administer the prescription benefits for Thompson Hine. Please update or create plan member profiles to reflect the changes regarding the following new plan adjudicating through CVS Caremark.

RXBIN: 004336

RXPCN: ADV

RXGRP: RX0453

Member ID Format: 11 digits, numeric only

Person Code: 2 digits, required

Card images are not available at this time.

Patient Pay Amount

Please rely on the claims system to determine the correct amount to collect from the plan member, if applicable.

Dear Valued Provider,

Effective December 1, 2016, Blue Cross and Blue Shield of Alabama (BCBS of AL) will be increasing the number of Prescribing Provider rejections Participating Pharmacies might receive for Commercial Covered Persons.

*Please see attached PDF for more information.

This is a reminder of the requirement to provide the "Medicare Prescription Drug Coverage and Your Rights" form to Medicare Part D enrollees whose claims are not paid under the Medicare Part D benefit. MedImpact is using NCPDP standard reject/approval codes that inform pharmacies to provide the standard "Medicare Prescription Drug Coverage and Your Rights" form to Medicare Part D enrollees. In addition, there is another MedImpact message to further explain why the notice needs to be provided to the beneficiary.

*Please see attached PDF for more information.